Resource Type

Journal Article 1

Year

2022 1

Keywords

advanced non-small-cell lung cancer 1

bevacizumab 1

elderly patient 1

overall survival 1

toxicity 1

Search scope:

排序： Display mode:

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 610-617 doi: 10.1007/s11684-021-0827-8

Abstract: Bevacizumab, an anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patientsHowever, the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require furtherThus, 59 patients were included in the present retrospective study, 22 patients in the bevacizumab plusfirst-line chemotherapy was an independent favorable prognostic factor for OS, whereas the addition of bevacizumabWith increased toxicities, the addition of bevacizumab to PP does not improve the overall survival of

Keywords： bevacizumab     elderly patient     advanced non-small-cell lung cancer     overall survival     toxicity    

HTML PDF Collect

Title Author Date Type Operation

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous

Journal Article